BioCentury | Sep 26, 2020
Finance

Data Bytes: oncology pair shines in NASDAQ debut as queue swells

...day on NASDAQ Friday, while ophthalmic play Graybug had a more modest debut on the exchange.PMV Pharmaceuticals Inc....
...above its offering price by Friday’s close.  TARGETSPRMT5 – Protein arginine methyltransferase 5 Paul Bonanos Prelude Therapeutics Inc. PMV Pharmaceuticals Inc. Graybug...
BioCentury | Aug 21, 2020
Product Development

Basket trials carry tumor-agnostic drug development forward

...their NASDAQ debut this year. A third, PMV Pharmaceuticals Inc....
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...for companies that have gone public on NASDAQ before entering the clinic, and two of PMV Pharmaceuticals Inc.’s...
...are Nextech Invest, Viking Global Investors and Boxer Capital of Tavistock Group. Elizabeth S. Eaton, Staff Writer PMV Pharmaceuticals Inc. p53...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH). Robin Sawka, BioCentury Staff Catalent Inc. Stanford University Intellia Therapeutics Inc. Cortexyme Inc. Chan Zuckerberg Biohub Grail Inc. PMV Pharmaceuticals Inc. Mirum...
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...promoted internally from within a healthcare VC firm in the last 15 years. Cancer company PMV Pharmaceuticals Inc....
...medical laboratory director. He was CSO and medical director at Exagen Inc. (NASDAQ:XGN). BioCentury Staff Alector Inc. Janpix Inc. PMV Pharmaceuticals Inc. Pyxis...
BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

...PMV raises $62M series C With plans to advance its p53-targeted candidates into the clinic, PMV Pharmaceuticals Inc....
...debt reduction (see “Buysiders on Board with BMS’s Plans for Otezla Cash” ). BioCentury Staff WinterLight Labs Inc. PMV Pharmaceuticals Inc. Novo...
BioCentury | Jun 14, 2019
Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

...commercialization manager at Knight Cancer Institute at Oregon Health & Science University. p53-targeting cancer company PMV Pharmaceuticals Inc....
...Co. (NYSE:BMY). Elizabeth S. Eaton, Staff Writer Xilio Therapeutics Inc. Amicus Therapeutics Inc. Lytix Biopharma A/S Mersana Therapeutics Inc. Oxford BioDynamics plc PMV Pharmaceuticals Inc. Precision...
BioCentury | Mar 19, 2018
Company News

Management tracks: J&J, Alder, CVS

...corporate strategy division. Hatanaka is a corporate officer and SVP, global development division. Cancer company PMV Pharmaceuticals Inc....
BioCentury | Dec 16, 2017
Company News

Management tracks: Chugai, bioMérieux

...stepping down. Mundipharma European Director of Commercial Operations Alberto Martinez will become CEO. Cancer company PMV Pharmaceuticals Inc....
BioCentury | Feb 24, 2017
Financial News

PMV Pharmaceuticals completes venture financing

...On Feb. 22, cancer company PMV Pharmaceuticals Inc. (Cranbury, N.J.) raised $74 million in a series B round...
...InterWest Partners , OrbiMed Advisors and Osage University Partners also participated. PMV Pharmaceuticals Inc. , Cranbury, N.J. Alicia Parker PMV Pharmaceuticals Inc....
Items per page:
1 - 10 of 16
BioCentury | Sep 26, 2020
Finance

Data Bytes: oncology pair shines in NASDAQ debut as queue swells

...day on NASDAQ Friday, while ophthalmic play Graybug had a more modest debut on the exchange.PMV Pharmaceuticals Inc....
...above its offering price by Friday’s close.  TARGETSPRMT5 – Protein arginine methyltransferase 5 Paul Bonanos Prelude Therapeutics Inc. PMV Pharmaceuticals Inc. Graybug...
BioCentury | Aug 21, 2020
Product Development

Basket trials carry tumor-agnostic drug development forward

...their NASDAQ debut this year. A third, PMV Pharmaceuticals Inc....
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...for companies that have gone public on NASDAQ before entering the clinic, and two of PMV Pharmaceuticals Inc.’s...
...are Nextech Invest, Viking Global Investors and Boxer Capital of Tavistock Group. Elizabeth S. Eaton, Staff Writer PMV Pharmaceuticals Inc. p53...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH). Robin Sawka, BioCentury Staff Catalent Inc. Stanford University Intellia Therapeutics Inc. Cortexyme Inc. Chan Zuckerberg Biohub Grail Inc. PMV Pharmaceuticals Inc. Mirum...
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...promoted internally from within a healthcare VC firm in the last 15 years. Cancer company PMV Pharmaceuticals Inc....
...medical laboratory director. He was CSO and medical director at Exagen Inc. (NASDAQ:XGN). BioCentury Staff Alector Inc. Janpix Inc. PMV Pharmaceuticals Inc. Pyxis...
BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

...PMV raises $62M series C With plans to advance its p53-targeted candidates into the clinic, PMV Pharmaceuticals Inc....
...debt reduction (see “Buysiders on Board with BMS’s Plans for Otezla Cash” ). BioCentury Staff WinterLight Labs Inc. PMV Pharmaceuticals Inc. Novo...
BioCentury | Jun 14, 2019
Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

...commercialization manager at Knight Cancer Institute at Oregon Health & Science University. p53-targeting cancer company PMV Pharmaceuticals Inc....
...Co. (NYSE:BMY). Elizabeth S. Eaton, Staff Writer Xilio Therapeutics Inc. Amicus Therapeutics Inc. Lytix Biopharma A/S Mersana Therapeutics Inc. Oxford BioDynamics plc PMV Pharmaceuticals Inc. Precision...
BioCentury | Mar 19, 2018
Company News

Management tracks: J&J, Alder, CVS

...corporate strategy division. Hatanaka is a corporate officer and SVP, global development division. Cancer company PMV Pharmaceuticals Inc....
BioCentury | Dec 16, 2017
Company News

Management tracks: Chugai, bioMérieux

...stepping down. Mundipharma European Director of Commercial Operations Alberto Martinez will become CEO. Cancer company PMV Pharmaceuticals Inc....
BioCentury | Feb 24, 2017
Financial News

PMV Pharmaceuticals completes venture financing

...On Feb. 22, cancer company PMV Pharmaceuticals Inc. (Cranbury, N.J.) raised $74 million in a series B round...
...InterWest Partners , OrbiMed Advisors and Osage University Partners also participated. PMV Pharmaceuticals Inc. , Cranbury, N.J. Alicia Parker PMV Pharmaceuticals Inc....
Items per page:
1 - 10 of 16